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Immunomodulating agents (ImiDs) are a novel class of anti-
cancer drugs that have demonstrated impressive antitumor
activity in various malignant disorders. Of this class, most
recent research has been focused on the remarkably active
agent, lenalidomide. Lenalidomide was designed to enhance
immunologic and anticancer properties while potentially
decreasing neurotoxic and teratogenic adverse effects of the
parent compound thalidomide.The introduction of this novel
agent has broadened the therapeutic landscape of hemato-
logic malignant disorders includingmultiple myeloma (MM)
and, more recently, other B-cell neoplasms. In this issue, we
focused on mechanisms of action and results from clinical
investigation that report the relevance of lenalidomide for the
treatment of B-cell disorders including MM, chronic lym-
phocytic leukaemia (CLL), and non-Hodgkin’s lymphomas
by offering new mechanisms for targeting these diseases.
In particular, papers defining the role of lenalidomide as
part of the induction therapy before hematopoietic stem
cells transplantation (HSCT) as well as its use as extended
maintenance therapy post-HSTC in patients with MM will
be of great interest.
In this special issue, we invited papers on potential topics
including, but are not limited to, lenalidomide: mechanism
of action, lenalidomide as part of the induction therapy
before HSCT and its use as consolidation and maintenance
therapy of multiple myeloma, lenalidomide in chronic lym-
phocytic leukaemia, lenalidomide in diffuse large B-cell
lymphoma, and lenalidomide in mantle cell and low-grade
non-Hodgkin’s lymphomas. Ten articles discuss the role of
lenalidomide in the treatment of malignant disorders.
The paper entitled “Lenalidomide in diffuse large B-cell
lymphoma” by C. Thieblemont et al. presents the biological
rational for the use of lenalidomide in DLBCL in light of
recent advances in the pathophysiology of the disease and
the therapeutic results of the most recent trials published
in literature or reported in meetings in relapsed/refractory
situations as well as in first-line treatment.The paper entitled
“Practical approaches to the use of lenalidomide in multiple
myeloma: a Canadian consensus” by D. Reece et al. discuss
the use of lenalidomide in the management of RRMM in
the Canadian environment. The Chair (DR) invited panelists
to research and write individual sections of the paper. The
various sections were collected, compiled, and distributed to
the group, which discussed the paper via web conference.
Panelists subsequently generated a revised draft in which
all sections included specific clinical guidance (i.e., practice
considerations). The revised paper was discussed at a final
web conference, where all practice recommendations were
considered, revised as appropriate, and ultimately adopted by
the full panel; any areas of disagreement are noted. Celgene
Canada provided the impetus for the panel to pursue this
project freely and independently. Celgene Canada supported
the process throughout, including support for the participa-
tion of a medical writer (JA) in preparing this paper. The
opinions represented here are solely those of the physician-
panelists.
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The paper entitled “Biological activity of lenalidomide
and its underlying therapeutic effects in multiple myeloma”
by R. Martiniani et al. is about the direct and indirect
antitumor effects of lenalidomide on malignant plasmacells,
bonemarrowmicroenvironment, bone resorption, and host’s
immune response. The molecular mechanisms and targets of
lenalidomide remain largely unknown, but recent evidence
shows cereblon (CRBN) as a possible mediator of its thera-
peutical effects.
The paper entitled “Molecular action of lenalidomide in
lymphocytes and hematologicmalignancies” by J.M.McDaniel
et al. summarizes the current information about lenalido-
mide in proliferative neoplasms and describes our under-
standing of the molecular mechanism of action in lympho-
cytes. Based on the overwhelming success of lenalidomide for
the treatment of several hematologic malignancies, there is
potential for therapies that augment host immune responses
to be extended from the relapsed and refractory setting, to
primary therapy.
The paper entitled “Secondary primary malignancies in
multiple myeloma: an old nemesis revisited” by J. Yang et
al. reviews the developmental history of myeloma therapy,
with particular emphasis on the risk of secondary cancers,
and examine the available data with regard to the risk
of SPMs seen with lenalidomide. We also speculate about
the mechanism(s) by which lenalidomide could increase
the risk of second cancers. To conclude, we make some
recommendations about how our current understanding
affects our treatment decisions and suggest directions for
future research. As new data emerge about lenalidomide and
the risk of SPMs, it is our hope that this paper will help to put
that information in proper perspective.
The paper entitled “Lenalidomide in the treatment of
young patients with multiple myeloma: from induction to
consolidation/maintenance therapy” by B. Lupo et al. presents
an overview of the results achieved with lenalidomide-
containing combinations in patients eligible for high-dose
therapies, namely, young patients. The advantages obtained
should always be outweighed with the toxicity profile asso-
ciated with the regimen used. Therefore, here, we will also
provide a description of the main adverse events associated
with lenalidomide and its combination.
The paper entitled “Lenalidomide in the treatment of
chronic lymphocytic leukemia” by A. Cortelezzi et al. provides
a comprehensive summary regarding mechanism of action,
efficacy, and safety of lenalidomide in CLL patients. Relevant
clinical trials using lenalidomide alone or in combination
are discussed. Lenalidomide shows good activity also in
relapsed/refractory or treatment-naive CLL patients. Defini-
tive data from ongoing studies are needed to validate overall
and progression-free survival.The toxicity profile might limit
lenalidomide use because it can result in serious side effects,
but largely controlled by gradual dose escalation. Further
understanding of the exact mechanism of action in CLL
will allow more efficacious use of lenalidomide alone or in
combination regimens.
The paper entitled “Lenalidomide in diffuse large B-
cell lymphomas” by A. Chiappella et al. reports the most
relevant clinical trials for the use of lenalidomide in DLBCL.
Monotherapy with lenalidomide showed an activity in terms
of overall response rate, with acceptable hematological and
extrahematological toxicities in relapsed/refractory aggres-
sive NHL. The role of lenalidomide as salvage therapy in
both cell of origin patterns in DLBCL (germinal center
B cell/activated B cell) was reported in preliminary data.
Preliminary data regarding the role of lenalidomide in addi-
tion to chemoimmunotherapy (R-CHOP) in first-line clinical
trials were discussed; data of safety, feasibility, and efficacy
were promising.
The paper entitled “Therapeutic activity of lenalidomide
in mantle cell lymphoma and indolent non-Hodgkin’s lym-
phomas” byM. Gunnellini et al. discusses the role of lenalido-
mide in the therapeutic armamentarium of patients with
indolent NHL or MCL.
The tenth paper entitled “Lenalidomide before and after
autologous hematopoietic stem cell transplantation in multiple
myeloma” by S. A. Tuchman et al. summarizes existing data
that pertains to lenalidomide in the specific context of ASCT,
and we share our thoughts on how our own group applies
these data to approach this complex issue clinically.
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